HMPL A83
Alternative Names: HMPL-A83Latest Information Update: 28 Jun 2025
At a glance
- Originator HUTCHMED
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- No development reported Haematological malignancies
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for preclinical development in Haematological-malignancies in Hong Kong (IV, Injection)
- 07 Apr 2025 Hutchmed completes a phase I trials in Solid tumours (Late-stage disease, Metastatic disease) in China (IV) (NCT05429008)
- 31 Dec 2022 HUTCHMED has patents pending for HMPL 283 in China, USA, Europe, Japan, Argentina and Taiwan